Expression of immune markers | Lymph node metastasis | Anatomic stage | Prognostic stage | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Absent (N = 154) | Present (N = 73) | P value | I&II (N = 189) | III (N = 38) | P value | I&II (N = 62) | III (N = 165) | P value | ||||
In tumor cells | ||||||||||||
PD-1 |  |  | – |  |  | – |  |  | – | |||
Positive (N = 0) | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  | |||
Negative (N = 227) | 154 (67.8%) | 73 (32.2%) |  | 189 (83.3%) | 38 (16.7%) |  | 62 (27.3%) | 165 (72.7%) |  | |||
PD-L1 | Â | Â | 0.779 | Â | Â | 0.038 | Â | Â | 0.342 | |||
Positive (N = 46) | 32 (69.6%) | 14 (30.4%) |  | 43 (93.5%) | 3 (6.5%) |  | 10 (21.7%) | 36 (78.3%) |  | |||
Negative (N = 181) | 122 (67.4%) | 59 (32.6%) |  | 146 (80.7%) | 65 (19.3%) |  | 52 (28.7%) | 129 (71.3%) |  | |||
PD-L2 | Â | Â | 0.324 | Â | Â | 0.299 | Â | Â | 0.723 | |||
Positive (N = 197) | 136 (69.0%) | 61 (31.0%) |  | 166 (84.3%) | 31 (15.7%) |  | 53 (26.9%) | 144 (73.1%) |  | |||
Negative (N = 30) | 18 (60%) | 12 (40%) |  | 23 (76.7%) | 7 (23.3%) |  | 9 (30.0% | 21 (70.0%) |  | |||
IDO | Â | Â | 0.313 | Â | Â | 0.884 | Â | Â | 0.711 | |||
Positive (N = 129) | 84 (65.1%) | 45 (34.9%) |  | 107 (82.9%) | 22 (17.1%) |  | 34 (26.4%) | 95 (73.6%) |  | |||
Negative (N = 98) | 70 (71.4%) | 28 (28.6%) |  | 82 (83.7%) | 16 (16.3%) |  | 28 (28.6%) | 70 (71.4%) |  | |||
TIM3 | Â | Â | 0.091 | Â | Â | 0.182 | Â | Â | 0.597 | |||
Positive (N = 109) | 68 (62.4%) | 41 (37.6%) |  | 87 (79.8%) | 22 (20.2%) |  | 28 (25.7%) | 81 (74.3%) |  | |||
Negative (N = 118) | 86 (79.2%) | 32 (27.1%) |  | 102 (86.4%) | 16 (13.6%) |  | 34 (28.8%) | 84 (71.2%) |  | |||
OX40 |  |  | 0.011 |  |  |  < 0.001 |  |  | 0.665 | |||
Positive (N = 82) | 47 (57.3%) | 32 (42.7%) |  | 56 (68.3%) | 26 (31.7%) |  | 21 (25.6%) | 61 (74.4%) |  | |||
Negative (N = 145) | 107 (73.8%) | 38 (23.2%) |  | 133 (91.7%) | 12 (8.3%) |  | 41 (28.3%) | 104 (71.7%) |  | |||
OX40L | Â | Â | 0.203 | Â | Â | 0.016 | Â | Â | 0.648 | |||
Positive (N = 86) | 54 (29.1%) | 32 (37.2%) |  | 65 (75.6%) | 21 (24.4%) |  | 22 (25.6%) | 64 (74.4%) |  | |||
Negative (N = 141) | 100 (70.9%) | 41 (62.8%) |  | 124 (87.9%) | 17 (12.1%) |  | 40 (28.4%) | 101 (71.6%) |  | |||
B7-H2 | Â | Â | 0.671 | Â | Â | 0.878 | Â | Â | 0.257 | |||
Positive (N = 193) | 132 (68.4%) | 61 (31.6%) |  | 161 (83.4%) | 32 (16.6%) |  | 50 (25.9%) | 143 74.1%) |  | |||
Negative (N = 34) | 22 (64.7%) | 12 (35.3%) |  | 28 (82.4%) | 6 (17.6%) |  | 12 (35.3%) | 22 (64.7%) |  | |||
In immune cells | ||||||||||||
PD-1 | Â | Â | 0.320 | Â | Â | 0.495 | Â | Â | 0.282 | |||
Positive (N = 126) | 82 (65.1%) | 44 (34.9%) |  | 103 (81.7%) | 23 (18.3%) |  | 38 (30.2%) | 88 (69.8%) |  | |||
Negative (N = 101) | 72 (71.3%) | 29 (28.7%) |  | 86 (85.1%) | 15 (14.9%) |  | 24 (23.8%) | 77 (76.2%) |  | |||
PD-L1 | Â | Â | 0.216 | Â | Â | 0.024 | Â | Â | 0.795 | |||
Positive (N = 91) | 66 (72.5%) | 25 (27.5%) |  | 82 (90.1%) | 9 (9.9%) |  | 24 (26.4%) | 67 (73.6%) |  | |||
Negative (N = 136) | 88 (64.7%) | 48 (35.3%) |  | 107 (78.7%) | 29 (21.3%) |  | 38 (27.9%) | 98 (72.1%) |  | |||
PD-L2 | Â | Â | 0.519 | Â | Â | 0.459 | Â | Â | 0.455 | |||
Positive (N = 108) | 71 (65.7%) | 37 (34.3%) |  | 92 (85.2%) | 16 (14.8%) |  | 32 (29.6%) | 76 (70.4%) |  | |||
Negative (N = 119) | 83 (69.7%) | 36 (30.3%) |  | 97 (81.5%) | 22 (18.5%) |  | 30 (25.2%) | 89 (74.8%) |  | |||
IDO | Â | Â | 0.451 | Â | Â | 0.642 | Â | Â | 0.536 | |||
Positive (N = 154) | 102 (66.2%) | 52 (33.8%) |  | 127 (82.5%) | 29 (17.5%) |  | 44 (28.6%) | 110 (71.4%) |  | |||
Negative (N = 73) | 52 (71.2%) | 21 (28.8%) |  | 62 (84.9%) | 11 (15.1%) |  | 18 (247%) | 55 (75.3%) |  | |||
TIM3 | Â | Â | 0.031 | Â | Â | 0.355 | Â | Â | 0.472 | |||
Positive (N = 104) | 63 (60.6%) | 41 (39.4%) |  | 84 (80.8%) | 20 (19.2%) |  | 26 (25.0%) | 78 (75.0%) |  | |||
Negative (N = 123) | 91 (74.0%) | 32 (26.0%) |  | 105 (85.4%) | 18 (14.6%) |  | 36 (29.3%) | 87 (70.7%) |  | |||
OX40 | Â | Â | 0.040 | Â | Â | 0.003 | Â | Â | 0.211 | |||
Positive (N = 84) | 50 (59.5%) | 34 (40.5%) |  | 62 (73.8%) | 22 (26.2%) |  | 27 (32.1%) | 57 (67.9%) |  | |||
Negative (N = 143) | 104 (72.7%) | 39 (27.3%) |  | 127 (88.8%) | 16 (11.2%) |  | 35 (24.5%) | 108 (75.5%) |  | |||
OX40L | Â | Â | 0.093 | Â | Â | 0.931 | Â | Â | 0.079 | |||
Positive (N = 103) | 64 (62.1%) | 39 (37.9%) |  | 86 (83.5%) | 17 (16.5%) |  | 34 (33.0%) | 69 (67.0%) |  | |||
Negative (N = 124) | 90 (72.6%) | 34 (27.4%) |  | 103 (83.1%) | 21 (16.9%) |  | 28 (22.6%) | 96 (77.4%) |  | |||
B7-H2 | Â | Â | 0.153 | Â | Â | 0.278 | Â | Â | 0.992 | |||
Positive (N = 150) | 97 (64.7%) | 53 (35.3%) |  | 122 (81.3%) | 29 (18.7%) |  | 41 (27.3%) | 109 (72.7%) |  | |||
Negative (N = 77) | 57 (74.0%) | 20 (26.0%) |  | 67 (87.0%) | 10 (13.0%) |  | 21 (27.3%) | 56 (72.7%) |  |